

Nicolas Picard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1658274/publications.pdf>

Version: 2024-02-01

61
papers

3,043
citations

172457

29
h-index

161849

54
g-index

66
all docs

66
docs citations

66
times ranked

3100
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Clinical Pharmacokinetics and Bayesian Estimators for the Individual Dose Adjustment of a Generic Formulation of Tacrolimus in Adult Kidney Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 611-622. | 3.5 | 9 |
| 2 | MRP4 is responsible for the efflux transport of mycophenolic acid β -glucuronide (MPAG) from hepatocytes to blood. <i>Xenobiotica</i> , 2021, 51, 105-114. | 1.1 | 5 |
| 3 | Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 150-200. | 2.0 | 89 |
| 4 | Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 647-654. | 2.0 | 1 |
| 5 | Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics. <i>Life Sciences</i> , 2019, 231, 116540. | 4.3 | 22 |
| 6 | Pharmacogenetics Biomarkers Predictive of Drug Pharmacodynamics as an Additional Tool to Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 121-130. | 2.0 | 6 |
| 7 | Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 261-307. | 2.0 | 374 |
| 8 | Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 361-365. | 2.3 | 9 |
| 9 | Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer. <i>International Journal of Legal Medicine</i> , 2017, 131, 979-988. | 2.2 | 38 |
| 10 | Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). <i>Therapie</i> , 2017, 72, 185-192. | 1.0 | 38 |
| 11 | Pharmacogenetics of immunosuppressants: State of the art and clinical implementation—Recommendations from the French National Network of Pharmacogenetics (RNPGx). <i>Therapie</i> , 2017, 72, 285-299. | 1.0 | 27 |
| 12 | Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. <i>Pharmacological Research</i> , 2017, 121, 138-144. | 7.1 | 25 |
| 13 | Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study. <i>BMC Cancer</i> , 2017, 17, 901. | 2.6 | 6 |
| 14 | Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S1-S20. | 2.0 | 78 |
| 15 | Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S80-S92. | 2.0 | 6 |
| 16 | Therapeutic Drug Monitoring of Everolimus. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 143-169. | 2.0 | 102 |
| 17 | Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. <i>Pharmacological Research</i> , 2016, 111, 501-508. | 7.1 | 19 |
| 18 | Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. <i>Transplantation</i> , 2016, 100, 2129-2137. | 1.0 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 684-692. | 2.0 | 2 |
| 20 | Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 204-214. | 1.2 | 1 |
| 21 | Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S57-S69. | 2.0 | 54 |
| 22 | New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs. <i>Pharmacogenomics</i> , 2016, 17, 277-296. | 1.3 | 25 |
| 23 | Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 484-489. | 3.0 | 25 |
| 24 | A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. <i>Pharmacogenomics</i> , 2016, 17, 375-391. | 1.3 | 13 |
| 25 | Genetic polymorphisms in the immune response: A focus on kidney transplantation. <i>Clinical Biochemistry</i> , 2016, 49, 363-376. | 1.9 | 9 |
| 26 | Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 3449-3456. | 3.7 | 10 |
| 27 | <i>UGT1A1</i> genotype and irinotecan therapy: general review and implementation in routine practice. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 219-237. | 1.9 | 91 |
| 28 | Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. <i>Pharmacogenomics</i> , 2015, 16, 1119-1134. | 1.3 | 39 |
| 29 | Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 256-262. | 1.5 | 27 |
| 30 | Severe Decrease of Cyclosporine Levels in a Heart Transplant Recipient Receiving the Direct Thrombin Inhibitor Argatroban. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 273-277. | 2.0 | 5 |
| 31 | The pharmacokinetic interaction between mycophenolic acid and cyclosporine revisited: a commentary on "Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus". <i>Xenobiotica</i> , 2013, 43, 836-838. | 1.1 | 10 |
| 32 | Involvement of UDP-Glucuronosyltransferases UGT1A9 and UGT2B7 in Ethanol Glucuronidation, and Interactions with Common Drugs of Abuse. <i>Drug Metabolism and Disposition</i> , 2013, 41, 568-574. | 3.3 | 73 |
| 33 | Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on Sirolimus In Vitro Metabolism and Trough Concentrations in Kidney Transplant Recipients. <i>Clinical Chemistry</i> , 2013, 59, 1761-1769. | 3.2 | 30 |
| 34 | Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 725-732. | 1.5 | 27 |
| 35 | Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 463-472. | 1.9 | 29 |
| 36 | Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatography-tandem mass spectrometry. <i>Analytical Biochemistry</i> , 2012, 427, 52-59. | 2.4 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 731-743. | 3.3 | 34 |
| 38 | Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica, 2011, 41, 752-757. | 1.1 | 23 |
| 39 | CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients. Transplantation, 2011, 91, 652-656. | 1.0 | 59 |
| 40 | Some lessons learned from using medium scale genotyping techniques in pharmacogenetic research. Clinical Chemistry and Laboratory Medicine, 2011, 49, 551-2. | 2.3 | 0 |
| 41 | Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenetics and Genomics, 2010, 20, 537-543. | 1.5 | 48 |
| 42 | Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the <i>UGT1A8*2</i> variant allele. British Journal of Clinical Pharmacology, 2010, 69, 675-683. | 2.4 | 40 |
| 43 | The Role of Organic Anion-Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2010, 87, 100-108. | 4.7 | 143 |
| 44 | Does Tacrolimus, in Comparison With Sirolimus, Increase Mycophenolic Acid Exposure in Kidney Transplant Recipients?. Clinical Pharmacology and Therapeutics, 2010, 87, 650-1. | 4.7 | 1 |
| 45 | Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up. Clinical Pharmacology and Therapeutics, 2010, 88, 95-100. | 4.7 | 66 |
| 46 | Contribution of the Different UDP-Glucuronosyltransferase (UGT) Isoforms to Buprenorphine and Norbuprenorphine Metabolism and Relationship with the Main UGT Polymorphisms in a Bank of Human Liver Microsomes. Drug Metabolism and Disposition, 2010, 38, 40-45. | 3.3 | 84 |
| 47 | Effect of Mycophenolate Acyl-Glucuronide on Human Recombinant Type 2 Inosine Monophosphate Dehydrogenase. Clinical Chemistry, 2009, 55, 986-993. | 3.2 | 31 |
| 48 | General unknown screening procedure for the characterization of human drug metabolites in forensic toxicology: Applications and constraints. Journal of Separation Science, 2009, 32, 3074-3083. | 2.5 | 46 |
| 49 | General unknown screening procedure for the characterization of human drug metabolites: Application to loratadine phase I metabolism. Journal of Separation Science, 2009, 32, 2209-2217. | 2.5 | 16 |
| 50 | Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients. Clinical Pharmacokinetics, 2009, 48, 805-816. | 3.5 | 117 |
| 51 | Genetic Variation in the Proximal Promoter of ABC and SLC Superfamilies: Liver and Kidney Specific Expression and Promoter Activity Predict Variation. PLoS ONE, 2009, 4, e6942. | 2.5 | 34 |
| 52 | Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenetics and Genomics, 2007, 17, 321-330. | 1.5 | 68 |
| 53 | Metabolism of Sirolimus in the Presence or Absence of Cyclosporine by Genotyped Human Liver Microsomes and Recombinant Cytochromes P450 3A4 and 3A5. Drug Metabolism and Disposition, 2007, 35, 350-355. | 3.3 | 39 |
| 54 | Is inappropriate medication use a major cause of adverse drug reactions in the elderly?. British Journal of Clinical Pharmacology, 2007, 63, 177-186. | 2.4 | 260 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Determination of Mycophenolic Acid Plasma Levels in Renal Transplant Recipients Co-administered Sirolimus: Comparison of an Enzyme Multiplied Immunoassay Technique (EMIT) and Liquid Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 274-277. | 2.0 | 46 |
| 56 | A comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 477-484. | 2.4 | 48 |
| 57 | A comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2006, . | 2.4 | 0 |
| 58 | IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYS. <i>Drug Metabolism and Disposition</i> , 2005, 33, 689-695. | 3.3 | 129 |
| 59 | IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM. <i>Drug Metabolism and Disposition</i> , 2005, 33, 139-146. | 3.3 | 251 |
| 60 | IN VITRO STUDY OF MYCOPHENOLIC ACID GLUCURONIDATION. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1524-1524. | 3.3 | 6 |
| 61 | Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 600-608. | 2.0 | 65 |